Physician profile
Edward C Reller
NPI 1023187424
$3,663.82
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $298 · 2021: $797 · 2022: $631 · 2023: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $464.49 | 2019-2021 | |
| Ucb, INC. | $406.46 | 2020-2023 | Briviact |
| Astrazeneca Pharmaceuticals LP | $374.17 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $372.56 | 2019-2023 | Ingrezza |
| Acadia Pharmaceuticals INC | $370.81 | 2021-2023 | Nuplazid |
| Greenwich Biosciences, INC. | $299.59 | 2019-2021 | |
| Sk Life Science, INC. | $230.36 | 2022-2023 | Xcopri |
| Avanir Pharmaceuticals, INC. | $175.27 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $174.13 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $144.44 | 2023 | Austedo Xr |
| Urovant Sciences INC | $134.39 | 2022 | |
| Neurelis, INC. | $124.01 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $121.91 | 2023 | Rexulti |
| Astellas Pharma US INC | $89.45 | 2020 | |
| Smith+Nephew, INC. | $85.76 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $82.86 | 2022 | |
| Kyowa Kirin, INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Reller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.